Outcomes of a 12-month course of early and late rituximab BCD020 biosimilar administration in juvenile systemic lupus erythematosus: A retrospective study
Elvira Kalashnikova, Eugenia Isupova, Ekaterina Gaidar, Natalia Lubimova, Lyubov Sorokina, Irina Chikova, Maria Kaneva, Rinat Raupov, Olga Kalashnikova, Damir Aliev, Inna Gaydukova, Mikhail Kostik · 2024
Read Outcomes of a 12-month course of early and late rituximab BCD020 biosimilar administration in juvenile systemic lupus erythematosus: A retrospective study by Elvira Kalashnikova, Eugenia Isupova, Ekaterina Gaidar, Natalia Lubimova, Lyubov Sorokina, Irina Chikova, Maria Kaneva, Rinat Raupov, Olga Kalashnikova, Damir Aliev, Inna Gaydukova, Mikhail Kostik (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11572657.txt.
Description
Elvira Kalashnikova and co-authors review rituximab use in children with lupus in a 2024 retrospective study. Juvenile systemic lupus is a severe, life-threatening disease, yet the role of rituximab in its care remains undefined. Early use of such biological therapy might improve outcomes, so timing was the key question.
The study followed a twelve-month course of a rituximab biosimilar called BCD020. It compared children treated early with those treated late in their disease. Comparing timing in real practice can guide families and doctors while the field still lacks definitive trials in this rare, serious condition.
Catalog record
| CREATOR | Elvira Kalashnikova, Eugenia Isupova, Ekaterina Gaidar, Natalia Lubimova, Lyubov Sorokina, Irina Chikova, Maria Kaneva, Rinat Raupov, Olga Kalashnikova, Damir Aliev, Inna Gaydukova, Mikhail Kostik |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |